**Robust IPO activity continues into late 2026 amid a record year for capital formation.** Through mid-2026, U.S. IPOs raised over $137 billion—far exceeding 2025 levels—with SPAC deals doubling and corporate offerings delivering significantly higher median proceeds around $200–280 million. Multiple listings are priced for mid-October, including Iambic Therapeutics (IAM) and City Therapeutics (CTY) on NASDAQ, alongside international debuts in Hong Kong and Japan. The pipeline reflects strong investor appetite for AI, biotech, and infrastructure names, yet rising Treasury yields (10-year near 19-year highs) and recent Fed rate hikes have prompted postponements for some larger candidates. Key near-term catalysts include Anthropic’s rumored October window, upcoming FOMC decisions, inflation data, and post-listing performance that could either sustain momentum or extend timelines into 2027 for select high-profile names. Trader sentiment aggregates these macro and deal-specific signals into implied probabilities for individual IPO resolutions by year-end.